CBD: Medicine from marijuana
GW Pharmaceuticals: Value Beyond Epidiolex? (NASDAQ:GWPH) | Seeking Alpha
GW cannabinoid drug fails midphase epilepsy trial | Fierce Biotech
US DEA action gives GW Pharma's CBD drug the go-ahead
GW Pharmaceuticals gets first FDA approval for CBD-based drug - MedCity News
GW Pharmaceuticals Announces Price for Their FDA-Approved CBD Medicine | The Marijuana Times
Epidiolex CBD Oil Approved by FDA to Treat Epilepsy
GW Pharmaceuticals | PotNetwork
Cannabinoids in Focus after GW Pharmaceuticals Snapped up for €6B
GW Pharmaceuticals Is One of TIME's 50 Genius Companies 2018 | Time.com
Cannabis Company GW Pharmaceuticals' Seizure Drug Flunks Phase II Trial | BioSpace
GW Pharma releases pricing on newly approved CBD-drug
GW Pharma Doubles Sales on Strong Uptake of CBD Drug Epidiolex - Mugglehead Magazine
GW Pharmaceuticals: Value Beyond Epidiolex? (NASDAQ:GWPH) | Seeking Alpha
GW Pharmaceuticals clinical trials indicate CBD helps Schizophrenia
How GW Pharma Won CBD - Cannabis Industry Journal
GW Pharmaceuticals' Epidiolex Receives Approval for Second Rare Disease Indication - Xtalks
BofA Sees Blockbuster Sales Potential For GW Pharma's CBD Drug Epidiolex
First prescription CBD from GW Pharma has restriction lowered
Jazz grows cannabinoid manufacturing ambitions with new $100M plant | Fierce Pharma
GW Pharmaceuticals May Get Marijuana-Based Therapy Approved in U.S. | Fortune
FDA Enforcement Against CBD Trade More Likely Following GW Drug Approval | Natural Products INSIDER
Medical cannabinoid firm GW Pharma to be acquired by Jazz Pharmaceuticals for $7.2 billion
GW Pharma Moves to Potentially Monopolize CBD Market – New Cannabis Ventures
